[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haemophilia-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haemophilia-a":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,63,85,111,134,160,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100491907","phase-3-a-research-study-looking-at-long-term-treatment-with-mim8-in-people-with-haemophilia-a-100491907",false,"NCT05685238","A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A","Open-label, Long-term Safety and Efficacy Study of Mim8 in Participants With Haemophilia A With or Without Inhibitors","FRONTIER4","Arm 1 \\& 2:\n\nInclusion Criteria:\n\n1. Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n2. Male or female with diagnosis of congenital haemophilia A based on medical records.\n3. Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728 at the time of transfer. Participant should qualify either of the following criteria:\n\n   1. Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,\n   2. Participant has completed the end of treatment visit for study NN7769-4514, NN7769-4516 or NN7769-4728.\n4. Participant and\u002For participant's parent(s)\u002Fparticipant's Legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.\n\nExclusion Criteria:\n\n1. Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n2. Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.\n3. Previous participation in this study. Participation is defined as signed informed consent.\n4. Female who is pregnant, breast-feeding or intends to become pregnant.\n5. Female of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures or as required by local regulation or practice).\n6. Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved investigational medicinal product.\n7. Any planned major surgery, during part 1 of the study.\n8. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.\n\nArm 3:\n\nInclusion criteria\n\n1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n2. Male or female with diagnosis of congenital severe haemophilia A (endogenous FVIII activity less than (\\\u003C) 1 percentage \\[%\\]) with or without FVIII inhibitors based on medical records.\n3. Aged \\\u003C1 year at the time of signing informed consent.\n4. Body weight greater than or equal to (≥) 3.2 kilograms at the time of signing informed consent.\n5. previously untreated patients (PUPs) or minimally treated patients (MTPs) (i.e., up to 5 days of exposure to haemophilia-related treatment such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products).\n6. Full-term pregnancy (gestational age ≥37 weeks).\n7. Participant's parent(s)\u002FLAR(s) willingness and ability to comply with scheduled visits and Arm 3 (infant) procedures, including the completion of diary and patient reported outcome (PRO) questionnaire.\n8. Participants \\\u003C3 months of age must show no signs of active intracranial haemorrhage at screening. This is confirmed by cranial ultrasound performed according to local practice and regardless of delivery method.\n9. Receipt of vitamin K prophylaxis (as per local standard practice).\n10. Availability of historical results in medical records for:\n\n    1. activated partial thromboplastin time (aPTT)\n    2. FVIII levels.\n11. Availability of historical results in medical records or pre-dose sample taken for:\n\n    1. fibrinogen\n    2. haematology parameters\n    3. biochemistry parameters (aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT), bilirubin and creatinine).\n\nExclusion criteria\n\n1. Known or suspected hypersensitivity to trial product or related products.\n2. Previous participation in study 4532. Participation is defined as signed informed consent.\n3. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of the last dose within 6 months (or 5 half-lives of the investigational medicinal product, whichever is shorter) before planned enrolment.\n4. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned enrolment.\n5. Known congenital or acquired coagulation disorders other than haemophilia A.\n6. Other conditions (e.g., autoimmune disease) or laboratory abnormality that may increase the risk of bleeding or thrombosis, as evaluated by the investigator. Any disorder, except for conditions associated with haemophilia A, that in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.\n7. Lack of adequate parental\u002Flegally acceptable representative (LAR) support to enter accurately and timely information regarding treatment and bleeding episodes into an (electronic) diary.\n8. Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease.\n9. Any planned major surgery, during part 1 of Arm 3 (infant). For definition of major surgery.\n10. Immune tolerance induction planned to take place after treatment initiation.\n11. Hepatic dysfunction defined as AST and\u002For ALT greater than (\\>) 3 times the upper limit of normal (ULN) combined with total bilirubin \\>1.5 times the ULN.\n12. Serum creatinine above 1.5 times the ULN.","ALL",{"count":19,"type":20},451,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in June 2028, whichever comes first. Participants will get up to 262 injections; the number of injections depends on how often participants will get injections and how long time participants take part in the study. While taking part in this study, there are some restrictions about what medicine participants can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.",[26,27],"Haemophilia A","Haemophilia A With Inhibitors","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2023-02-13",{"date":36,"type":20},"2028-06-30",{"name":38,"class":39},"Novo Nordisk A\u002FS","INDUSTRY",152,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100641810","patient-preferences-in-treatment-of-haemophilia-a-with-and-without-inhibitors-a-discrete-choice-experiment-in-germany-100641810","NCT07653139","Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n* Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.\n* Age above or equal to 18 years at the time of signing informed consent.\n* Validated diagnose with haemophilia A, with and without inhibitors.\n* Resident in Germany.\n\nExclusion Criteria:\n\n* No provision of informed consent in this study.\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n* Age below 18 years at the time of signing informed consent.\n* Absence of a diagnosis of haemophilia A.\n* No residence in Germany.","18 Years",{"count":49,"type":20},150,"OBSERVATIONAL","This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.",[26],"NOT_YET_RECRUITING","2026-06-11",{"date":56,"type":32},"2026-06-17",{"date":58,"type":20},"2026-07-10",{"date":60,"type":20},"2026-10-26",{"name":38,"class":39},1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100339167","efficacy-safety--utilisation-of-nuwiq-octanate-and-wilate-in-previously-untreated--minimally-treated-haemophilia-a-patients-100339167","NCT03695978","Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated & Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment With Nuwiq, Octanate or Wilate - Efficacy & Safety Observational Study-Protect-NOW","Protect-NOW","Inclusion Criteria:\n\n* Male and female patients of any age and ethnicity\n* Severe haemophilia A (FVIII:C\\\u003C1%)\n* Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study\n* Either\n* No previous treatment with FVIII concentrates or other blood products containing FVIII (PUPs) OR\n* Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood products containing FVIII (MTPs), if\n* data are available on all previous treatment, AND\n* they did not develop an inhibitor at any time point, OR\n* they developed an inhibitor during treatment with an Octapharma FVIII concentrate AND continue treatment with THIS Octapharma FVIII concentrate (in the presence or absence of emicizumab).\n* Voluntarily given, fully informed written and signed consent obtained before any study-related data documentation is conducted (obtained from the patient's parent\u002Flegal guardian)\n\nExclusion Criteria:\n\n* Diagnosis with a coagulation disorder other than haemophilia A\n* Concomitant treatment with any systemic immunosuppressive drug\n* Participation in an interventional clinical trial during the time period evaluated\n* Participation in another non-interventional study of Octapharma",{"count":72,"type":20},200,"International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.",[26],"2026-05-29",{"date":77,"type":32},"2026-06-02",{"date":79,"type":32},"2018-02-13",{"date":81,"type":20},"2030-06",{"name":83,"class":39},"Octapharma",59,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":47,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100609898","phase-1-a-research-study-looking-at-how-different-doses-of-study-medicine-inno8-work-in-the-body-of-people-with-haemophilia-a-100609898","NCT07220564","A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A","VOYAGER2","Inclusion Criteria:\n\n* Male\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Body weight greater than or equal to (≥) 45 kilograms (kgs).\n* Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (≤) 15 percentage (%) with or without FVIII inhibitors, based on medical records.\n\nExclusion Criteria:\n\n* Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal product by the time of screening.\n* Body mass index ≥30.0 kilogram per square meter (kg\u002Fm\\^2).\n* Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.\n* Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.\n* Any known coagulation disorders other than haemophilia A.\n* Ongoing or planned immune tolerance induction therapy.\n* Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and\u002For nutrients, as judged by the investigator.",true,"MALE","64 Years",{"count":97,"type":20},30,[99],"PHASE1","This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.",[26],"2026-04-23",{"date":104,"type":32},"2026-04-24",{"date":106,"type":32},"2025-10-23",{"date":108,"type":20},"2027-02-05",{"name":38,"class":39},33,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":94,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":62},"100225096","a-survey-on-the-success-of-inhibitor-elimination-using-individualized-concentrate-selection-and-controlled-iti-100225096","NCT02207894","A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI","A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled (High Dose) Immune Tolerance Induction (ITI)","Inclusion Criteria:\n\n* Based on the decision of the treating physicians in the participating centres, male patients at any age suffering from severe (FVIII activity \\\u003C 1%), moderate (FVIII activity \\>1% - 5%), or mild (FVIII activity \\> 5%) haemophilia A will be included into this post marketing observation if relevant inhibitor levels (\\> 0.6 BU) have been detected, or - in case of an inhibitor level \\\u003C0.6 BU - with reduced recovery or half-life of FVIII.\n* The observation is also open for patients who failed an earlier ITI attempt.\n\nExclusion Criteria:\n\n* Female",{"count":119,"type":20},300,"This research program is initiated to evaluate and document data on the success of ITI in 300 haemophilia A patients with newly developed or already existing FVIII-inhibitors (also patients who might potentially have failed in earlier ITIs), which will be treated with ITI - preferably high-dose based on individualized product selection, in order to improve management of this potentially devastating complication of haemophilia treatment.\n\nIn order to investigate the role of in vitro tests on individual ITI success rate in patients undergoing ITI, the inhibitor plasma samples can be assayed against different FVIII concentrates using the following in vitro tests: Batch selection, Thrombin generation assay (TGA), Thrombin Generation Test (TGT) to monitor FVIII efficacy, Epitope mapping,IgG Subclasses specific for FVIII, Immunogenotyping.",[26],[123],"Haemophilia A, factor VIII, development of inhibitor","2026-04-20",{"date":126,"type":32},"2026-04-21",{"date":128,"type":4},"2006-08",{"date":130,"type":20},"2027-12",{"name":132,"class":133},"Haemophilia Centre Rhine Main","OTHER",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":94,"minAge":4,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":62},"100626574","phase-3-efficacy-and-safety-evaluation-study-of-sct800-in-previously-untreated-hemophilia-a-patients-100626574","NCT07437404","Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.","An Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.","Inclusion Criteria:\n\n* Male subjects with severe hemophilia A (FVIII:C \\\u003C 1% in central laboratory tests)\n* previously untreated with pdFVIII\u002FrFVIII, including marketed SCT800 (those who have previously used ≤5EDs of blood products such as cryoprecipitate or fresh frozen plasma are acceptable).\n* FVIII inhibitor negative\n* informed consent.\n\nExclusion Criteria:\n\n* Known allergy to recombinant coagulation factor VIII concentrate or any excipient; known allergy to bovine, rodent or hamster bovine;\n* subjects with a history or family history of FVIII inhibitor formation;\n* Clinical liver function test (ALT、AST) ≥ 5 ULN or clinical kidney function test (BUN，Cr) ≥2 ULN;\n* Patients with other coagulation dysfunction diseases in addition to hemophilia A.\n* International Normalized Ratio (INR) \\> 1.5.","6 Years",{"count":143,"type":20},36,[23],"This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.",[26],[148,149,150],"SCT800","haemophilia A","previously untreated patients","2026-02-23",{"date":153,"type":32},"2026-02-27",{"date":155,"type":32},"2024-04-26",{"date":157,"type":20},"2028-12-26",{"name":159,"class":39},"Sinocelltech Ltd.",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":94,"minAge":47,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":62},"100487028","an-observational-research-study-of-the-health-of-joints-in-people-with-haemophilia-taking-the-medicine-esperoct-100487028","NCT05621746","An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct","Non-Interventional Study of the Change in Joint Health in Adult Patients With Haemophilia A After Switching to Prophylaxis With Turoctocog Alfa Pegol (N8-GP)","Inclusion Criteria:\n\n* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n* Male, greater than or equal to 18 years of age at the time of signing informed consent, diagnosed with severe (FVIII activity below 1%) or moderate congenital haemophilia A (FVIII activity 1-5%).\n* The decision to initiate treatment with commercially available Esperoct has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.\n* Switched, within two months prior to enrolment, OR planned to switch, within one month post enrolment, to prophylaxis treatment with Esperoct from previous therapy; the decision to initiate treatment with Esperoct must be made prior to and independently from the decision to enrol in the study.\n* Must have baseline data (HJHS, target joints, and medical history) collected in routine clinical practice within two months prior or up to one month post switch to Esperoct therapy.\n\nExclusion Criteria:\n\n* Previous participation in this study. Participation is defined as having given informed consent in this study.\n* Previous terminated treatment regimen with Esperoct prophylaxis.\n* Current or previously terminated treatment regimen with Esperoct on-demand.\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.\n* Previous participation in a clinical trial within the 30 days prior to switching to Esperoct.",{"count":168,"type":20},100,"This study will collect information on the long term health of joints in people with haemophilia A who have started treatment with Esperoct within twelve months prior to participation to the study. This study is conducted to look at how joint health of people with haemophilia changes over time when they are receiving the medicine Esperoct. The participants will get Esperoct as prescribed to the participants by the study doctor. The participant's treatment will not be affected by their involvement in the study. Every six months, the participants will be asked to answer some questionnaires about their joints, their pain and their ability to be physically active. Their participation in the study will last for no more than 2 years. The participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.",[26],"2025-05-30",{"date":173,"type":32},"2025-06-02",{"date":175,"type":32},"2022-11-23",{"date":31,"type":20},{"name":38,"class":39},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":94,"minAge":47,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":200,"locationsCount":62},"100543157","prevalence-of-synovitis-in-patients-with-haemophilia-a-100543157","NCT06352216","Prevalence of Synovitis in Patients With Haemophilia A","Prevalence of Synovitis in Adult Patients With Haemophilia A in Germany and Austria","SynoPrev","Inclusion Criteria:\n\n* Participants (≥ 18 years old) suffering from moderate or severe haemophilia A, also with inhibitor or joint replacement\n* Complete documentation of hemophilia severity, treatment history (past 12 months), and bleeding events (past 12 months), inhibitor status (at time of enrollment and in past medical history)\n* Submitted written consent to participate in the study\n\nExclusion Criteria:\n\n* Patients suffering from other bleeding disorders conflicting with the research question\n* Patients in clinical studies with investigational drugs",{"count":119,"type":20},"The aim of this study is to evaluate the prevalence of synovitis in adult patients with haemophilia A.",[26,189,190,191],"Synovitis","Hemophilia Arthropathy","Sonography",[189,26,193],"Prevalence","2024-04-15",{"date":196,"type":32},"2024-04-16",{"date":194,"type":32},{"date":199,"type":20},"2027-03",{"name":201,"class":133},"University Hospital, Bonn"]